SIGA Technologies Q1 revenue falls, net loss widens

SIGA Technologies

07/05/2026 21:43

Overview

U.S. infectious disease drugmaker's Q1 revenue fell yr/yr, net loss widened

Company declared and paid special $0.60 per share cash dividend in Q1

SIGA entered exclusive license agreement for oral TPOXX in MENA region

Outlook

SIGA expects to deliver $13 mln of oral TPOXX to an international customer in Q2 2026

Company plans to deliver $26 mln of IV TPOXX to U.S. Government by end of Q3 2026

SIGA says focus remains on securing new procurement contracts and orders to drive business

Result Drivers

INTERNATIONAL EXPANSION - Co signed exclusive license agreement for oral TPOXX in MENA region

UPCOMING CONTRACT DELIVERIES - Co expects to deliver $13 mln of oral TPOXX to Asia Pacific customer in Q2 and $26 mln of IV TPOXX to U.S. government by end of Q3

Company press release: ID:nGNX78zc2H

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.05
Q1 Net Income
-$3.5 mln


Analyst Coverage

The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 4 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)